B. Riley Securities Reiterates Buy Rating on CLPT with $30 Target
B. Riley Securities maintains its buy rating on CLPT, setting a price target of $30, a 78.47% upside from the current price.
Key Points
- B. Riley Securities reiterated its buy rating on CLPT, setting a $30 price target on June 18, 2026.
- B. Riley Securities's $30 price target implies 78.47% upside from ClearPoint Neuro, Inc.'s ($CLPT) current $16.81 share price.
- CLPT shares are trading at $16.81, with notable insider buying activity in recent months.
- Institutional investors like BlackRock and Geode Capital have adjusted their positions in CLPT.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 18, 2026, B. Riley Securities reiterated its buy rating for CLPT, setting a price target of $30. Shares of CLPT are currently trading at $16.81, reflecting the firm's continued confidence in the company's potential.
Analysts Set New Price Targets
On June 18, 2026, B. Riley Securities maintained its buy rating on CLPT, with analyst Anderson Schock setting a price target of $30. This follows a series of buy ratings from B. Riley Securities, which previously set targets of $20 and $18 earlier in the year. The consistent buy ratings highlight the firm's bullish outlook on CLPT's future performance.
Other Institutional Activity in CLPT
Several institutional investors have been active in CLPT recently. BlackRock, Inc. increased its holdings by 39,117 shares, bringing its total to 2,082,750 shares valued at approximately $18.95 million. Geode Capital Management, LLC also added 51,375 shares, ending with 705,720 shares worth about $6.42 million. Meanwhile, Lane Generational LLC made a substantial increase, adding 146,242 shares to its portfolio, resulting in a total of 486,849 shares valued at $4.43 million.
Insider Buying and Selling at ClearPoint Neuro, Inc.
Insider activity at CLPT has been notable. On June 4, 2026, Timothy Richards sold 500 shares at $10 each and bought 500 shares on the same day. Additionally, he sold 376 shares at $13.30 and 5,415 shares at $12.17 earlier in June. Meanwhile, Linda Liau and John Fletcher each purchased 12,820 shares at no cost on May 21, 2026, indicating a strategic interest in the company's stock.
Bottom Line
B. Riley Securities' reiteration of its buy rating for CLPT with a $30 price target suggests confidence in the company's prospects. The stock is trading at $16.81, and recent insider buying activity and institutional adjustments highlight ongoing interest in CLPT. Investors often track these ratings and activities to gauge market sentiment, though it's important to remember that analyst ratings are forward-looking estimates.
Get ClearPoint Neuro, Inc. alerts
New 13F filings, insider trades, and analyst moves on $CLPT, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.